| 薛乐刚,柏凤,程亮,翟其金,汤道权.恩格列净联合α-硫辛酸对T2DM伴ACI患者糖代谢及神经功能的影响.[J].中南医学科学杂志.,2021,(5):532-535. |
| 恩格列净联合α-硫辛酸对T2DM伴ACI患者糖代谢及神经功能的影响 |
| Effect of Enpagliflozin combined with α-lipoic acid on the efficacy, glucose metabolism and neurological function of patients with T2DM and ACI |
| 投稿时间：2021-02-12 修订日期：2021-04-25 |
| DOI：10.15972/j.cnki.43-1509/r.2021.05.008 |
| 中文关键词: 恩格列净 α-硫辛酸 2型糖尿病 急性脑梗死 糖代谢 神经功能 |
| 英文关键词:empagliflozin α-lipoic acid type 2 diabetes acute cerebral infarction glucose metabolism nerve function |
| 基金项目:江苏省高校自然科学研究重大项目(16KJA350001)；江苏省第九批“六大人才高峰”高层次人才项目(YY-013)；淮安市卫生健康科研立项项目(HAWJ201915) 作者简介:薛乐刚,主管药师,研究方向为临床药学,E-mail为xueleganga@163.com。通信作者汤道权,博士,教授,硕士研究生导师,研究方向为药物动力学、体内药物分析,E-mail为tangdq@xzhmu.edu.cn。 |
| 作者 | 单位 | E-mail | | 薛乐刚 | 徐州医科大学附属淮安医院药学部,,江苏省淮安市223002 | e-mail为xueleganga@163.com,e-mail为tangdq@xzhmu.edu.cn | | 柏凤 | 徐州医科大学附属淮安医院内分泌科,,江苏省淮安市223002 | | | 程亮 | 徐州医科大学附属淮安医院内分泌科,,江苏省淮安市223002 | | | 翟其金 | 徐州医科大学附属淮安医院神经内科,江苏省淮安市223002 | | | 汤道权 | 药物分析教研室,江苏省徐州市221004 | e-mail为xueleganga@163.com,e-mail为tangdq@xzhmu.edu.cn |
|
| 摘要点击次数: 404 |
| 全文下载次数: 239 |
| 中文摘要: |
| 目的探究恩格列净联合α-硫辛酸对2型糖尿病(T2DM)伴急性脑梗死(ACI)患者的疗效、糖代谢及神经功能的影响。方法选择106例T2DM伴ACI患者,随机法均分为联合组及对照组。在常规药物治疗基础上,对照组采用恩格列净治疗,联合组采用恩格列净联合α-硫辛酸治疗。观察治疗后6周疗效(NIHSS评分)及不良反应、6周空腹血糖(FPG)、空腹胰岛素(Fins)、餐后2 h血糖(2hPBG)及糖化白蛋白(GA)、血清簇集蛋白及血栓素B2(TXB2)、前列腺素F1α(PGF1α)水平。结果联合组NIHSS评分有效率较对照组明显升高(P＜0.05)。与治疗前比较,联合组和对照组患者治疗后FPG、Fins、2hPBG和GA水平均明显降低(P＜0.05),且联合组治疗后低于对照组(P＜0.05)。联合组治疗后血清簇集蛋白、TXB2和TXB2/PGF1α低于对照组,PGF1α明显高于对照组(P＜0.05)。结论恩格列净联合α-硫辛酸用药可提高T2DM伴ACI患者的疗效,改善糖代谢及神经功能,不良反应少,值得临床推广。 |
| 英文摘要: |
| To explore the effect of combination of empagliflozin and α-lipoic acid on type 2 diabetes (T2DM) patients with acute cerebral infarction (ACI), glucose metabolism and nerve function. Methods106 T2DM patients with ACI were selected, and randomly divided into combined group and control group. All selected individuals received routine treatment, based on this, control group received empagliflozin, while combined group received empagliflozin combined with α-lipoic acid. Six weeks after treatment, various indexes were observed in both groups, including clinical efficacy, adverse reactions, levels of fasting plasma glucose (FPG), fasting insulin (Fins), 2 h postprandial blood glucose (2hPBG), glycated albumin (GA), cluster (CLU), plasma thromboxane B2 (TXB2) and prostaglandin F1α (PGF1α). ResultsThe efficacy rate related to National Institute of Health Stroke Scale (NIHSS) score was significantly higher in combined group than in control group (P＜0.05). After treatment, there was a significant decrease in FPG, Fins, 2hPBG and GA levels in both groups (P＜0.05), and the decrease was more significant in combined group than in control group (P＜0.05). Compared with control group, combined group had significantly lower levels of CLU, TXB2 and TXB2/PGF1α as well as higher PGF1α level after treatment (P＜0.05). ConclusionApplication of empagliflozin combined with α-lipoic acid can effectively ameliorate the glucose metabolism and neurological functions for T2DM patients with ACI, with fewer adverse reactions, which is worthy of clinical promotion. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|